9 Recruiting Leukemia Phase 1 / Phase 2 Clinical Trials
Active phase 1 / phase 2 studies for leukemia enrolling across the USA. Verify eligibility and contact site coordinators.
All Leukemia studiesPhase 1 / Phase 2 Studies for Leukemia
🔵 Active, Not Recruiting Phase1 / Phase2
Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
📍 Memorial Sloan Kettering Cancer Center — New York, New York
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 / Phase2
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
📍 University of Chicago — Chicago, Illinois
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 / Phase2
Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 / Phase2
A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma
📍 Children's Hospital Los Angeles — Los Angeles, California
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
📍 Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2
Mosunetuzumab for CLL MRD Clearance
📍 Brigham & Women's Hospital — Boston, Massachusetts
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2
CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL
📍 University of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2
A Study of Revumenib and Mezigdomide in People With Leukemia
📍 City of Hope Cancer Center (Data collection only) — Duarte, California
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔